JP7871246B2 - コンジュゲート型ヘプシジン模倣体 - Google Patents

コンジュゲート型ヘプシジン模倣体

Info

Publication number
JP7871246B2
JP7871246B2 JP2023505923A JP2023505923A JP7871246B2 JP 7871246 B2 JP7871246 B2 JP 7871246B2 JP 2023505923 A JP2023505923 A JP 2023505923A JP 2023505923 A JP2023505923 A JP 2023505923A JP 7871246 B2 JP7871246 B2 JP 7871246B2
Authority
JP
Japan
Prior art keywords
lys
hepcidin
item
analog
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023505923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536463A (ja
JP2023536463A5 (cg-RX-API-DMAC7.html
Inventor
グレゴリー トーマス ボーン,
アショク バンダーリー,
ジエ ザン,
ブライアン トロイ フレデリック,
マーク レスリー スマイス,
Original Assignee
プロタゴニスト セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス, インコーポレイテッド filed Critical プロタゴニスト セラピューティクス, インコーポレイテッド
Publication of JP2023536463A publication Critical patent/JP2023536463A/ja
Publication of JP2023536463A5 publication Critical patent/JP2023536463A5/ja
Priority to JP2025186320A priority Critical patent/JP2026012422A/ja
Application granted granted Critical
Publication of JP7871246B2 publication Critical patent/JP7871246B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2023505923A 2020-07-28 2021-07-28 コンジュゲート型ヘプシジン模倣体 Active JP7871246B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025186320A JP2026012422A (ja) 2020-07-28 2025-11-05 コンジュゲート型ヘプシジン模倣体

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063057574P 2020-07-28 2020-07-28
US202063057577P 2020-07-28 2020-07-28
US202063057582P 2020-07-28 2020-07-28
US202063057583P 2020-07-28 2020-07-28
US63/057,574 2020-07-28
US63/057,583 2020-07-28
US63/057,577 2020-07-28
US63/057,582 2020-07-28
US202163169515P 2021-04-01 2021-04-01
US202163169527P 2021-04-01 2021-04-01
US202163169533P 2021-04-01 2021-04-01
US63/169,533 2021-04-01
US63/169,515 2021-04-01
US63/169,527 2021-04-01
PCT/US2021/043579 WO2022026629A1 (en) 2020-07-28 2021-07-28 Conjugated hepcidin mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025186320A Division JP2026012422A (ja) 2020-07-28 2025-11-05 コンジュゲート型ヘプシジン模倣体

Publications (3)

Publication Number Publication Date
JP2023536463A JP2023536463A (ja) 2023-08-25
JP2023536463A5 JP2023536463A5 (cg-RX-API-DMAC7.html) 2024-07-16
JP7871246B2 true JP7871246B2 (ja) 2026-06-08

Family

ID=80036079

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023505923A Active JP7871246B2 (ja) 2020-07-28 2021-07-28 コンジュゲート型ヘプシジン模倣体
JP2023505864A Pending JP2023540679A (ja) 2020-07-28 2021-07-28 コンジュゲートされたヘプシジン模倣物
JP2025186320A Pending JP2026012422A (ja) 2020-07-28 2025-11-05 コンジュゲート型ヘプシジン模倣体
JP2025253353A Pending JP2026048851A (ja) 2020-07-28 2025-12-16 コンジュゲートされたヘプシジン模倣物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023505864A Pending JP2023540679A (ja) 2020-07-28 2021-07-28 コンジュゲートされたヘプシジン模倣物
JP2025186320A Pending JP2026012422A (ja) 2020-07-28 2025-11-05 コンジュゲート型ヘプシジン模倣体
JP2025253353A Pending JP2026048851A (ja) 2020-07-28 2025-12-16 コンジュゲートされたヘプシジン模倣物

Country Status (10)

Country Link
US (3) US20240018189A1 (cg-RX-API-DMAC7.html)
EP (2) EP4188413A4 (cg-RX-API-DMAC7.html)
JP (4) JP7871246B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230053615A (cg-RX-API-DMAC7.html)
AU (2) AU2021316000A1 (cg-RX-API-DMAC7.html)
CA (2) CA3189432A1 (cg-RX-API-DMAC7.html)
IL (1) IL299530A (cg-RX-API-DMAC7.html)
MX (1) MX2023001292A (cg-RX-API-DMAC7.html)
PH (1) PH12023500004A1 (cg-RX-API-DMAC7.html)
WO (3) WO2022026631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2022212696A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2022212698A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US20250170216A1 (en) * 2022-02-02 2025-05-29 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4536683A4 (en) * 2022-06-07 2026-06-10 Protagonist Therapeutics Inc HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526634A (ja) 1999-12-03 2003-09-09 ブリストル−マイヤーズ スクイブ ファーマ カンパニー C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤
JP2015504859A (ja) 2011-12-09 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改変ミニヘプシジンペプチドおよびその使用方法
JP2016521257A (ja) 2013-03-15 2016-07-21 プロタゴニスト セラピューティクス, インコーポレイテッド ヘプシジン類似体及びその使用
JP2017523959A (ja) 2014-06-27 2017-08-24 プロタゴニスト セラピューティクス, インコーポレイテッド ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
KR20170002414A (ko) * 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
WO2018128828A1 (en) * 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526634A (ja) 1999-12-03 2003-09-09 ブリストル−マイヤーズ スクイブ ファーマ カンパニー C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤
JP2015504859A (ja) 2011-12-09 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改変ミニヘプシジンペプチドおよびその使用方法
JP2016521257A (ja) 2013-03-15 2016-07-21 プロタゴニスト セラピューティクス, インコーポレイテッド ヘプシジン類似体及びその使用
JP2017523959A (ja) 2014-06-27 2017-08-24 プロタゴニスト セラピューティクス, インコーポレイテッド ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clark RJ et al.,Design, synthesis, and characterization of cyclic analogues of the iron regulatory peptide hormone hepcidin,Biopolymers,2013年,vol.100(5),pp.519-526

Also Published As

Publication number Publication date
JP2026012422A (ja) 2026-01-23
AU2021316000A1 (en) 2023-02-16
MX2023001292A (es) 2023-02-22
WO2022026629A1 (en) 2022-02-03
CA3189432A1 (en) 2022-02-03
US20240066131A1 (en) 2024-02-29
WO2022026633A1 (en) 2022-02-03
EP4188412A4 (en) 2024-10-23
US20240018189A1 (en) 2024-01-18
JP2026048851A (ja) 2026-03-17
US20230295259A1 (en) 2023-09-21
EP4188412A1 (en) 2023-06-07
EP4188413A1 (en) 2023-06-07
WO2022026631A1 (en) 2022-02-03
KR20230053615A (ko) 2023-04-21
IL299530A (en) 2023-02-01
EP4188413A4 (en) 2025-03-05
JP2023536463A (ja) 2023-08-25
PH12023500004A1 (en) 2023-08-14
JP2023540679A (ja) 2023-09-26
AU2021315564A1 (en) 2023-02-09
CA3188410A1 (en) 2022-02-03

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260527

R150 Certificate of patent or registration of utility model

Ref document number: 7871246

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150